This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug |
Toxicity |
Interaction Type |
Mechanism |
Reference |
|---|
| Amitriptyline (50-48-6) | Abnormal Behaviour | Synergistic | Not understood | Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?
|
| Amitriptyline (50-48-6) | Asystole | Synergistic | Not understood | Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?
|
| Amitriptyline (50-48-6) | Diaphoresis | Synergistic | Not understood | Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?
|
| Amitriptyline (50-48-6) | Hypertension | Synergistic | Not understood | Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?
|
| Amitriptyline (50-48-6) | Mental Status Changes | Synergistic | Not understood | Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?
|
| Amitriptyline (50-48-6) | Muscular Rigidity Spastic | Synergistic | Not understood | Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?
|
| Amitriptyline (50-48-6) | Seizures | Synergistic | Not understood | Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?
|
| Amitriptyline (50-48-6) | Syncope | Synergistic | Not understood | Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?
|
| Ephedrine (299-42-3) | Hypertensive Crisis | Synergistic | Ephedrine is an indirectly-acting sympathomimetic that causes increased release of noradrenaline; selegiline has some MAO-A ininhibitory activity and may therefore inhibit noradrenaline metabolism | Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline
|
| Fluoxetine (54910-89-3) | Shivering | Synergistic | Not understood | Interaction of fluoxetine and selegiline
|
| Fluvoxamine (54739-18-3) | Cns Toxicity | Synergistic | Not understood | Movement Disorders : A Brief Guide in Medication Management
|
| Fluvoxamine (54739-18-3) | Increased Muscle Tone | Synergistic | Not understood | Movement Disorders : A Brief Guide in Medication Management
|
| Fluvoxamine (54739-18-3) | Myoclonus | Synergistic | Not understood | Movement Disorders : A Brief Guide in Medication Management
|
| Fluvoxamine (54739-18-3) | Shivering | Synergistic | Not understood | Movement Disorders : A Brief Guide in Medication Management
|
| Pethidine (57-42-1) | Hypotension | Synergistic | Not understood, | Severe adverse interaction between pethidine and selegiline
|
| Tranylcypromine (155-09-9) | Hypotension | Synergistic | Not understood | Attempts to attenuate the 'cheese effect' Combined drug therapy in depressive illness
|
| Levacetylmethadol (1477-40-3) | Cardiac Arrhythmias | Antagonistic | Prolong the QT interval | The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone
|
| Levodopa (59-92-7) | Agitation | Additive | MAO-B inhibitors prevent the metabolism of dopamine, therefore additive dopaminergic effects occur with levodopa. | Movement Disorders : A Brief Guide in Medication Management
|
| Levodopa (59-92-7) | Cardiac Arrhythmias | Additive | MAO-B inhibitors prevent the metabolism of dopamine, therefore additive dopaminergic effects occur with levodopa. | Movement Disorders : A Brief Guide in Medication Management
|
| Levodopa (59-92-7) | Confusion | Additive | MAO-B inhibitors prevent the metabolism of dopamine, therefore additive dopaminergic effects occur with levodopa. | Movement Disorders : A Brief Guide in Medication Management
|
| Levodopa (59-92-7) | Dyskinesia | Additive | MAO-B inhibitors prevent the metabolism of dopamine, therefore additive dopaminergic effects occur with levodopa. | Movement Disorders : A Brief Guide in Medication Management
|
| Levodopa (59-92-7) | Hallucinations | Additive | MAO-B inhibitors prevent the metabolism of dopamine, therefore additive dopaminergic effects occur with levodopa. | Movement Disorders : A Brief Guide in Medication Management
|
| Levodopa (59-92-7) | Headache | Additive | MAO-B inhibitors prevent the metabolism of dopamine, therefore additive dopaminergic effects occur with levodopa. | Movement Disorders : A Brief Guide in Medication Management
|
| Levodopa (59-92-7) | Nausea | Additive | MAO-B inhibitors prevent the metabolism of dopamine, therefore additive dopaminergic effects occur with levodopa. | Movement Disorders : A Brief Guide in Medication Management
|
| Levodopa (59-92-7) | Postural Hypotension | Additive | MAO-B inhibitors prevent the metabolism of dopamine, therefore additive dopaminergic effects occur with levodopa. | Movement Disorders : A Brief Guide in Medication Management
|
| Levodopa (59-92-7) | Vertigo | Additive | MAO-B inhibitors prevent the metabolism of dopamine, therefore additive dopaminergic effects occur with levodopa. | Movement Disorders : A Brief Guide in Medication Management
|